These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27012781)

  • 21. VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel.
    Cubero Gómez JM; Acosta Martínez J; Mendias Benítez C; Díaz De La Llera LS; Fernández-Quero M; Guisado Rasco A; Villa Gil-Ortega M; Sánchez González Á
    Acta Cardiol; 2015 Dec; 70(6):728-34. PubMed ID: 26717223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome.
    Wakabayashi S; Kitahara H; Nishi T; Sugimoto K; Nakayama T; Fujimoto Y; Ariyoshi N; Kobayashi Y
    Cardiovasc Interv Ther; 2018 Jul; 33(3):239-246. PubMed ID: 28608310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
    Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction.
    Alexopoulos D; Theodoropoulos KC; Stavrou EF; Xanthopoulou I; Kassimis G; Tsigkas G; Damelou A; Davlouros P; Hahalis G; Athanassiadou A
    Cardiovasc Drugs Ther; 2012 Oct; 26(5):393-400. PubMed ID: 22930115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crushed/chewed administration of potent P2Y
    Guo C; Zhao JR; Chen MJ; Zhang Y; Wu RY; Li QQ; Zhao H; Wei J
    Platelets; 2022 Jul; 33(5):679-686. PubMed ID: 34472997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Aitmokhtar O; Paganelli F; Benamara S; Azaza A; Bonello L; Hamza O; Seddiki S; Benathmane T; Saidane M; Bouzid A; Kara M; Sik A; Azzouz A; Harbi F; Monsuez JJ; Benkhedda S
    Arch Cardiovasc Dis; 2017 Nov; 110(11):626-633. PubMed ID: 28583820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Onset of antiplatelet action with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: pharmacodynamic study.
    Alexopoulos D; Makris G; Xanthopoulou I; Patsilinakos S; Deftereos S; Gkizas V; Perperis A; Karanikas S; Angelidis C; Tsigkas G; Koutsogiannis N; Hahalis G; Davlouros P
    Circ Cardiovasc Interv; 2014 Apr; 7(2):233-9. PubMed ID: 24668226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COMparison of Platelet reactivity following prAsugrel and ticagrelor loading dose in ST-Segment elevation myocardial infarctION patients: The COMPASSION study.
    Laine M; Gaubert M; Frère C; Peyrol M; Thuny F; Yvorra S; Chelini V; Bultez B; Luigi S; Mokrani Z; Bessereau J; Toesca R; Champenois A; Dignat-George F; Paganelli F; Bonello L
    Platelets; 2015; 26(6):570-2. PubMed ID: 25275609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Capranzano P; Capodanno D; Bucciarelli-Ducci C; Gargiulo G; Tamburino C; Francaviglia B; Ohno Y; La Manna A; Antonella S; Attizzani GF; Angiolillo DJ; Tamburino C
    Eur Heart J Acute Cardiovasc Care; 2016 Sep; 5(5):475-86. PubMed ID: 26758542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-hospital treatment with crushed versus integral tablets of prasugrel in patients presenting with ST-Segment Elevation Myocardial Infarction-1-year follow-up results of the COMPARE CRUSH trial.
    Vogel RF; Delewi R; Wilschut JM; Lemmert ME; Diletti R; van Vliet R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Smits PC; Van Mieghem NM; Vlachojannis GJ
    Am Heart J; 2022 Oct; 252():26-30. PubMed ID: 35671829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study.
    Parodi G; Valenti R; Bellandi B; Migliorini A; Marcucci R; Comito V; Carrabba N; Santini A; Gensini GF; Abbate R; Antoniucci D
    J Am Coll Cardiol; 2013 Apr; 61(15):1601-6. PubMed ID: 23500251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers.
    Hobl EL; Reiter B; Schoergenhofer C; Schwameis M; Derhaschnig U; Lang IM; Stimpfl T; Jilma B
    Clin Res Cardiol; 2016 Apr; 105(4):349-55. PubMed ID: 26493304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prasugrel or Ticagrelor in ST-Segment-Elevation Myocardial Infarction Patients With Diabetes Mellitus.
    Sardella G; Mancone M; Stio RE; Cavallo E; Di Roma A; Colantonio R; Calcagno S
    Circulation; 2017 Aug; 136(6):602-604. PubMed ID: 28784829
    [No Abstract]   [Full Text] [Related]  

  • 37. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
    Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamic Assessment of Platelet Reactivity After a Loading Dose of Prasugrel or Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction.
    Ichikawa S; Tsukahara K; Minamimoto Y; Kimura Y; Matsuzawa Y; Maejima N; Iwahashi N; Hibi K; Kosuge M; Ebina T; Kimura K
    Circ J; 2016 Nov; 80(12):2520-2527. PubMed ID: 27725493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) Study.
    Franchi F; Rollini F; Ortega-Paz L; Been L; Giordano S; Galli M; Ghanem G; Garabedian H; Al Saleh T; Uzunoglu E; Rivas A; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Mahowald M; Reiter B; Jilma B; Angiolillo DJ
    JACC Cardiovasc Interv; 2023 Oct; 16(20):2528-2539. PubMed ID: 37609698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial".
    Kedhi E; Fabris E; van der Ent M; Kennedy MW; Buszman P; von Birgelen C; Cook S; Wedel H; Zijlstra F
    Am Heart J; 2017 Jun; 188():11-17. PubMed ID: 28577666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.